Secondary analysis of the SUPREMO trial: in 989 UK women with intermediate-risk breast cancer after mastectomy, chest wall radiotherapy worsened chest wall symptoms at 5 years versus none (effect estimate 1·99; p=0·017), with no significant differences in other QOL domains.
Secondary analysisn = 989
Velikova et al. Postmastectomy chest wall radiotherapy for breast cancer (SUPREMO): 5-year quality-of-life results from a randomised, controlled, phase 3 trial